Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease

/PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases,...

Related Keywords

Berwyn ,Pennsylvania ,United States ,Marial Maccecchini ,Nic Johnson ,Annovis Bio ,Exchange Commission ,Linkedin ,Movement Disorder Society ,Twitter ,Annovis Bio Inc ,Russo Partners ,Disorder Society Sponsored Revision ,Unified Parkinson ,Disease Rating Scale ,Participant Global Impression ,Wechsler Adult Intelligence Scale ,Mini Mental State Examination ,Annual Report ,Investor Contact ,